Lantern Pharma, Inc. (LTRN)
1.80
-0.04
(-2.17%)
USD |
NASDAQ |
Sep 09, 12:39
Lantern Pharma Shareholders Equity (Quarterly) : -3.217M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.217M |
| March 31, 2026 | 3.446M |
| December 31, 2025 | 6.534M |
| September 30, 2025 | 9.587M |
| June 30, 2025 | 12.52M |
| March 31, 2025 | 16.78M |
| December 31, 2024 | 21.19M |
| September 30, 2024 | 26.60M |
| June 30, 2024 | 30.93M |
| March 31, 2024 | 35.77M |
| December 31, 2023 | 40.91M |
| September 30, 2023 | 45.41M |
| June 30, 2023 | 48.26M |
| Date | Value |
|---|---|
| March 31, 2023 | 52.58M |
| December 31, 2022 | 56.04M |
| September 30, 2022 | 59.03M |
| June 30, 2022 | 61.08M |
| March 31, 2022 | 65.32M |
| December 31, 2021 | 71.57M |
| September 30, 2021 | 75.73M |
| June 30, 2021 | 79.61M |
| March 31, 2021 | 81.73M |
| December 31, 2020 | 19.70M |
| September 30, 2020 | 21.57M |
| June 30, 2020 | 23.23M |
| March 31, 2020 | 0.5365M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.48M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 8.602M |
| Total Liabilities (Quarterly) | 11.82M |
| Debt to Equity Ratio | -0.0123 |
| Current Ratio | 1.957 |
| Net Debt Paydown Yield | 0.06% |